Chronic Obstructive Pulmonary Disease Patients Have Increased Levels of Plasma Inflammatory Mediators Reported Upregulated in Severe COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Chronic obstructive pulmonary disease (COPD) is associated with increased risk of severe COVID-19, but the mechanisms are unclear. Besides, patients with severe COVID-19 have been reported to have increased levels of several immune mediators.
Methods
Ninety-two proteins were quantified in 315 plasma samples from 118 asthmatics, 99 COPD patients and 98 healthy controls (age 40-90 years), who were recruited in Colombia before the COVID-19 pandemic. Protein levels were compared between each disease group and healthy controls. Significant proteins were compared to the gene signatures of SARS-CoV-2 infection reported in the “COVID-19 Drug and Gene Set Library” and with experimentally tested protein biomarkers of severe COVID-19.
Results
Forty-one plasma proteins showed differences between patients and controls. Asthmatic patients have increased levels in IL-6 while COPD patients have a broader systemic inflammatory dysregulation driven by HGF, OPG, and several chemokines (CXCL9, CXCL10, CXCL11, CX3CL1, CXCL1, MCP-3, MCP-4, CCL3, CCL4 and CCL11). These proteins are involved in chemokine signaling pathways related with response to viral infections and some, were found up-regulated upon SARS-CoV-2 experimental infection of Calu-3 cells as reported in the COVID-19 Related Gene Sets database. An increase of HPG, CXCL9, CXCL10, IL-6, MCP-3, TNF and EN-RAGE has also been experimentally detected in patients with severe COVID-19.
Conclusions
COPD patients have altered levels of plasma proteins that have been reported increased in patients with severe COVID-19. Our study suggests that COPD patients have a systemic dysregulation in chemokine networks (including HGF and CXCL9) that could make them more susceptible to severe COVID-19. Also, that IL-6 levels are increased in some asthmatic patients (especially in females) and this may influence their response to COVID-19. The findings in this study depict a novel panel of inflammatory plasma proteins in COPD patients that may potentially associate with increased susceptibility to severe COVID-19 and might be useful as a biomarker signature after future experimental validation.
Article activity feed
-
-
-
SciScore for 10.1101/2021.01.23.21250370: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the ethical committees of the University of Cartagena (nr. 4169722017) and the “Fundación Neumológica Colombiana” (nr. 232-07122017) and written informed consent was obtained from all participants.
Consent: Inclusion criteria were no exacerbation in the last eight weeks, age 40 or more, with a clinical diagnosis of asthma or COPD confirmed by a pneumologist and signed informed consent.Randomization Quantification of plasma proteins: For plasma profiling the samples were randomly distributed in 96-well plates and protein levels were measured by the Proximity Extension Assay (PEA) [18] using the Target 96 Inflammation Panel ( Blinding n… SciScore for 10.1101/2021.01.23.21250370: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the ethical committees of the University of Cartagena (nr. 4169722017) and the “Fundación Neumológica Colombiana” (nr. 232-07122017) and written informed consent was obtained from all participants.
Consent: Inclusion criteria were no exacerbation in the last eight weeks, age 40 or more, with a clinical diagnosis of asthma or COPD confirmed by a pneumologist and signed informed consent.Randomization Quantification of plasma proteins: For plasma profiling the samples were randomly distributed in 96-well plates and protein levels were measured by the Proximity Extension Assay (PEA) [18] using the Target 96 Inflammation Panel ( Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources IgE antibodies were measured by ImmunoCAP following manufacturer instructions (Thermo Fisher, Uppsala, Sweden) IgEsuggested: NoneSoftware and Algorithms Sentences Resources (https://www.r-project.org/). https://www.r-project.org/suggested: (R Project for Statistical Computing, RRID:SCR_001905)Functional annotation: The list of proteins with differences between patients and healthy controls were analysed for pathways, ontologies, diseases/drugs in the Enrichr web tool (https://maayanlab.cloud/Enrichr/) [31]. Enrichrsuggested: (Enrichr, RRID:SCR_001575)The induced network analysis was constructed in Consensus PathDB (http://cpdb.molgen.mpg.de/) using an intermediate nodes z-score threshold of 30 and including binary protein-protein interactions of high confidence and biochemical reactions [33]. http://cpdb.molgen.mpg.de/suggested: (ConsensusPathDB, RRID:SCR_002231)The search engine Geneshot (https://amp.pharm.mssm.edu/geneshot/) was used to systematically retrieve known markers associated with SARS infection and to calculate the probability of detecting overlap due to chance with the protein list resulting from this study. Geneshotsuggested: (Geneshot, RRID:SCR_017582)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-